A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma Treated with Talimogene Laherparepvec
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms TVEC-325
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 02 Aug 2016 Planned End Date changed from 1 Dec 2018 to 1 Jun 2018.
- 02 Aug 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2017.